PORCN and hepatocellular carcinoma: CGX1321, a PORCN inhibitor, is currently in a phase 1 trial as a monotherapy in patients with advanced GI tumors, including HCC, with a roll-over cohort in combination with pembrolizumab in patients that have progressed on single-agent CGX1321 [104] (Table 2).